Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3V0HA)

Drug Name

FR230513 Drug Info

Synonyms

FR230513; 1-((1R)-1-(HYDROXYMETHYL)-3-(1-NAPHTHYL)PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE; 1ndy; AC1L9KR0; DB03572; 1-[(2R)-1-hydroxy-4-naphthalen-1-ylbutan-2-yl]imidazole-4-carboxamide; 1-[(2R)-1-hydroxy-4-(naphthalen-1-yl)butan-2-yl]imidazole-4-carboxamide; 1-[(1R)-1-(hydroxymethyl)-3-(1-naphthyl)propyl]imidazole-4-carboxamide; 1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide; 1H-Imidazole-4-carboxamide, 1-[1-(hydroxymethyl)-3-(1-naphthalenyl)propyl]-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 447341
TTD Drug ID: DM3V0HA

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adenosine deaminase (ADA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[2]
Elapegademase	DMS7OU8	Adenosine deaminase defciency	4A01.1	Approved	[3]
Fludarabine	DMVRLT7	Acute myelogenous leukaemia	2A41	Approved	[4]
Pentostatin	DM0HXDS	Acute graft versus host disease	4B24.0	Approved	[4]
GSK2696273	DMP5O1U	Chronic pain	MG30	Preregistration	[5]
OTL-101	DMLMS6J	Severe combined immunodeficiency	4A01.10	Phase 3	[6]
Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy	DMIREUZ	Immunodeficiency	4A00-4A85	Phase 1/2	[5]
EHNA	DM014WS	Discovery agent	N.A.	Investigative	[7]
3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol	DMZT8QX	Discovery agent	N.A.	Investigative	[8]
3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol	DMAIS1D	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline.
6	Clinical pipeline report, company report or official report of Orchard Therapeutics.
7	Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67.
8	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.